New combo aims to shrink liver tumors in colorectal cancer patients
NCT ID NCT07515963
First seen Apr 09, 2026 · Last updated Jun 16, 2026 · Updated 13 times
Summary
This study tests a chemotherapy regimen called FULIRI combined with targeted drugs (bevacizumab or cetuximab) as a first treatment for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors enough so that they can be surgically removed or treated with radiation. About 24 adults aged 18-75 who have not had prior treatment for their liver metastases will participate. The main measure of success is how many patients see their tumors shrink significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430071, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.